Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$6.88 +5.5%	$7.11	$2.32 ▼ $9.90	$372.15M	2.47	984,909 shs	362,286 shs
NBTX Nanobiotix	$10.09 +3.6%	$6.11	$2.76 ▼ $10.59	$483.95M	0.45	13,300 shs	41,490 shs
OLMA Olema Pharmaceuticals	$5.76 +4.0%	$4.79	$2.86 ▼ $13.93	$395.33M	1.92	535,497 shs	432,641 shs
PLRX Pliant Therapeutics	$1.45	$1.44	$1.10 ▼ $16.10	$89.01M	1.42	1.02 million shs	619,819 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	+5.52%	+0.88%	-13.02%	+6.83%	-27.88%
NBTX Nanobiotix	+3.59%	+27.56%	+73.22%	+165.60%	+112.42%
OLMA Olema Pharmaceuticals	+3.97%	+4.54%	+23.61%	+14.29%	-53.55%
PLRX Pliant Therapeutics	0.00%	-6.45%	-8.23%	+12.40%	-89.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.9437 of 5 stars	2.3	1.0	0.0	2.2	1.7	0.0
NBTX Nanobiotix	0.8793 of 5 stars	1.3	3.0	0.0	3.5	0.0	0.6
OLMA Olema Pharmaceuticals	1.6565 of 5 stars	3.3	0.0	0.0	2.5	2.5	0.0
PLRX Pliant Therapeutics	3.5818 of 5 stars	3.0	2.0	4.7	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	10.05% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	-20.71% Downside
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	316.67% Upside
PLRX Pliant Therapeutics	2.08	Hold	$8.19	464.66% Upside

Current Analyst Ratings Breakdown

Latest PLRX, NBTX, OLMA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/10/2025	PLRX Pliant Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
8/8/2025	PLRX Pliant Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $4.00
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	4.65	N/A	N/A	$3.96 per share	1.74
NBTX Nanobiotix	$39.18M	12.35	N/A	N/A	($1.51) per share	-6.68
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.03 per share	N/A
PLRX Pliant Therapeutics	$1.58M	56.34	N/A	N/A	$3.59 per share	0.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	11/11/2025 (Estimated)
PLRX Pliant Therapeutics	-$210.30M	-$3.40	N/A	N/A	N/A	N/A	-73.45%	-55.66%	11/6/2025 (Estimated)

Latest PLRX, NBTX, OLMA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A
8/7/2025	Q2 2025	PLRX Pliant Therapeutics	-$0.62	-$0.71	-$0.09	-$0.71	N/A	N/A
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	24.42	24.42
NBTX Nanobiotix	N/A	1.04	1.04
OLMA Olema Pharmaceuticals	0.01	11.09	11.09
PLRX Pliant Therapeutics	0.14	12.99	12.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
NBTX Nanobiotix	38.81%
OLMA Olema Pharmaceuticals	91.78%
PLRX Pliant Therapeutics	97.30%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
NBTX Nanobiotix	3.45%
OLMA Olema Pharmaceuticals	16.36%
PLRX Pliant Therapeutics	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
NBTX Nanobiotix	100	47.94 million	46.29 million	Not Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.48 million	Optionable

PLRX, NBTX, OLMA, and FULC Headlines

Recent News About These Companies

Needham Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

August 21 at 1:31 PM | theglobeandmail.com

Citi Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)

August 21 at 1:31 PM | theglobeandmail.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Hold" by Brokerages

August 13, 2025 | americanbankingnews.com

Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi

August 11, 2025 | msn.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Hold" from Brokerages

August 9, 2025 | marketbeat.com

Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $4.00 at Piper Sandler

August 9, 2025 | marketbeat.com

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

XTX Topco Ltd Makes New $630,000 Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

August 6, 2025 | marketbeat.com

Pliant Therapeutics (PLRX) Expected to Announce Earnings on Wednesday

July 30, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)

July 24, 2025 | theglobeandmail.com

Pliant Therapeutics Provides Update on BEACON-IPF

June 27, 2025 | globenewswire.com

Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo

June 7, 2025 | msn.com

Pliant Therapeutics presents new fibrosis treatment data

May 23, 2025 | investing.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | finance.yahoo.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | globenewswire.com

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Pliant Therapeutics announces workforce reduction

May 3, 2025 | uk.investing.com

Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials

May 3, 2025 | nasdaq.com

Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value

May 2, 2025 | msn.com

Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials

May 2, 2025 | biospace.comB

Pliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woes

May 2, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, NBTX, OLMA, and FULC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$6.88 +0.36 (+5.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.88 +0.00 (+0.01%)

As of 08/22/2025 05:10 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Nanobiotix NASDAQ:NBTX

$10.09 +0.35 (+3.59%)

Closing price 08/22/2025 03:51 PM Eastern

Extended Trading

$10.35 +0.26 (+2.58%)

As of 08/22/2025 05:27 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Olema Pharmaceuticals NASDAQ:OLMA

$5.76 +0.22 (+3.97%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.76 0.00 (-0.09%)

As of 08/22/2025 04:10 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Pliant Therapeutics NASDAQ:PLRX

$1.45 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.34%)

As of 08/22/2025 05:51 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time